Prevalence of malaria relapse: systematic review with meta-analysis.
Nascimento TLD, Vasconcelos SP, Peres Y, Oliveira MJS, Taminato M, Souza KMJ.
Rev Lat Am Enfermagem. 2019 Mar 18;27:e3111. doi: 10.1590/1518-8345.2619.3111.
Relapse.
White NJ, Imwong M.
Adv Parasitol. 2012;80:113-50. doi: 10.1016/B978-0-12-397900-1.00002-5.
Recent trends and perspectives on malaria relapse: A mini review.
Radha B, Bharti PK, Rahi M, Baharia RK.
J Vector Borne Dis. 2025 Jul 1;62(3):261-273. doi: 10.4103/jvbd.jvbd_66_24. Epub 2025 Jan 18.
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Rodrigo C, Rajapakse S, Fernando D.
Cochrane Database Syst Rev. 2020 Sep 6;9(9):CD010458. doi: 10.1002/14651858.CD010458.pub3.
Determinants of relapse periodicity in Plasmodium vivax malaria.
White NJ.
Malar J. 2011 Oct 11;10:297. doi: 10.1186/1475-2875-10-297.
Relapse or reinfection: Classification of malaria infection using transition likelihoods.
Lin FC, Li Q, Lin JT.
Biometrics. 2020 Dec;76(4):1351-1363. doi: 10.1111/biom.13226. Epub 2020 Mar 3.
The hypnozoite and relapse in primate malaria.
Cogswell FB.
Clin Microbiol Rev. 1992 Jan;5(1):26-35. doi: 10.1128/CMR.5.1.26.
Primaquine treatment and relapse in Plasmodium vivax malaria.
Rishikesh K, Saravu K.
Pathog Glob Health. 2016;110(1):1-8. doi: 10.1080/20477724.2015.1133033. Epub 2016 Feb 18.
Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area.
Wångdahl A, Sondén K, Wyss K, Stenström C, Björklund D, Zhang J, Hervius Askling H, Carlander C, Hellgren U, Färnert A.
Clin Infect Dis. 2022 Apr 9;74(7):1199-1207. doi: 10.1093/cid/ciab610.
Single dose tafenoquine for preventing relapse in people with plasmodium vivax malaria-an updated meta-analysis.
Anjum MU, Naveed AK, Mahmood SN, Naveed OK.
Travel Med Infect Dis. 2020 Jul-Aug;36:101576. doi: 10.1016/j.tmaid.2020.101576. Epub 2020 Feb 6.
